Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Down 53.7% in April

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a large drop in short interest in April. As of April 30th, there was short interest totaling 37,414 shares, a drop of 53.7% from the April 15th total of 80,782 shares. Approximately 1.5% of the shares of the stock are sold short. Based on an average daily volume of 137,830 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Investors Weigh In On Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC bought a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent filing with the SEC. 20.34% of the stock is currently owned by institutional investors and hedge funds.

Catheter Precision Price Performance

Shares of VTAK stock traded down $0.01 during trading hours on Friday, reaching $0.76. The company’s stock had a trading volume of 33,645 shares, compared to its average volume of 81,516. The firm’s 50 day simple moving average is $1.08 and its 200-day simple moving average is $1.68. The company has a market capitalization of $2.05 million, a price-to-earnings ratio of -0.04 and a beta of -1.04. Catheter Precision has a fifty-two week low of $0.76 and a fifty-two week high of $15.68. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.46.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.